Exelixis
EXEL
#1688
Rank
ยฃ8.07 B
Marketcap
ยฃ28.27
Share price
2.24%
Change (1 day)
64.29%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Net assets

Net assets on the balance sheet as of September 2024 : ยฃ1.80 Billion

According to Exelixis's latest financial reports the company has ยฃ1.80 Billion in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

Exelixis - Net assets on balance sheet (from 2001 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$ยฃ1.77 B-13.61%
2022-12-31$ยฃ2.05 B25.6%
2021-12-31$ยฃ1.63 B18.79%
2020-12-31$ยฃ1.37 B7.22%
2019-12-31$ยฃ1.28 B26.76%
2018-12-31$ยฃ1.01 B381.04%
2017-12-31$ยฃ0.21 B191.28%
2016-12-31$ยฃ72.38 M-176.18%
2015-12-31$-ยฃ95.02 Million28.83%
2014-12-31$-ยฃ73.76 Million-283.67%
2013-12-31$ยฃ40.15 M-78.11%
2012-12-31$ยฃ0.18 B214.53%
2011-12-31$ยฃ58.31 M-139.42%
2010-12-31$-ยฃ0.15 Billion46.19%
2009-12-31$-ยฃ0.11 Billion163.57%
2008-12-31$-ยฃ38.39 Million-189.18%
2007-12-31$ยฃ43.04 M-6.95%
2006-12-31$ยฃ46.25 M39.23%
2005-12-31$ยฃ33.22 M25.88%
2004-12-31$ยฃ26.39 M-70.76%
2003-12-31$ยฃ90.27 M-17.72%
2002-12-31$ยฃ0.10 B-32.94%
2001-12-31$ยฃ0.16 B

Net assets for similar companies or competitors

Company Net assets differencediff. Country
ยฃ14.29 B 691.26%๐Ÿ‡ฌ๐Ÿ‡ง UK
ยฃ62.11 B 3,339.00%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ35.37 B 1,858.32%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ13.65 B 655.90%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ5.97 B 230.80%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ55.69 B 2,983.30%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ73.47 B 3,967.73%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ0.56 Million-100.03%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ22.89 M-98.73%๐Ÿ‡บ๐Ÿ‡ธ USA